[HTML][HTML] Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV …
V Gounden, C Van Niekerk, T Snyman… - AIDS research and …, 2010 - Springer
Abstract Background The 516G> T polymorphism in exon 4 of the CYP2B6 gene has been
associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations …
associated with increased plasma Efavirenz (EFV) concentrations. EFV concentrations …
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study
DW Haas, HJ Ribaudo, RB Kim, C Tierney… - Aids, 2004 - journals.lww.com
Objectives: Efavirenz is an effective antiretroviral agent, but central nervous system side
effects occur commonly, and population (racial) differences in pharmacokinetics and …
effects occur commonly, and population (racial) differences in pharmacokinetics and …
Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients
W Manosuthi, C Sukasem… - Antimicrobial agents …, 2013 - Am Soc Microbiol
Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6)
polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in …
polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in …
Homozygous CYP2B6* 6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing …
K Tsuchiya, H Gatanaga, N Tachikawa, K Teruya… - Biochemical and …, 2004 - Elsevier
Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver. We analyzed
the genotypes of CYP2B6 and their contribution to plasma EFV concentrations in 35 EFV …
the genotypes of CYP2B6 and their contribution to plasma EFV concentrations in 35 EFV …
Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms
T Lindfelt, J O'Brien, JC Song, R Patel… - Annals of …, 2010 - journals.sagepub.com
Background: Interpatient variability in efavirenz concentrations may be due to CYP2B6
genetic polymorphisms. Efavirenz concentration and pharmacogenomic data are scarce in …
genetic polymorphisms. Efavirenz concentration and pharmacogenomic data are scarce in …
Effects of rifampicin, CYP2B6 and ABCB1 polymorphisms on efavirenz plasma concentration in Chinese patients living with HIV and tuberculosis
L Zhang, X Meng, P Dong, T Qi… - … journal of STD & …, 2023 - journals.sagepub.com
Background Tuberculosis (TB) is the leading opportunistic infection of people living with
human immunodeficiency virus (HIV; PLWH). Cytochrome P450 (CYP) 2B6 and ATP …
human immunodeficiency virus (HIV; PLWH). Cytochrome P450 (CYP) 2B6 and ATP …
[HTML][HTML] Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without …
Objectives Plasma efavirenz concentrations in HIV-infected patients with tuberculosis (TB)
may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and …
may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and …
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti
DW Haas, P Severe, MA Jean Juste… - Journal of …, 2014 - academic.oup.com
Objectives Efavirenz is widely prescribed for HIV-1 infection. Three polymorphisms in
CYP2B6 define plasma efavirenz trough concentration strata that vary across an∼ 10-fold …
CYP2B6 define plasma efavirenz trough concentration strata that vary across an∼ 10-fold …
CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV‐infected patients
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Cytochrome P450 (CYP) 2B6
polymorphisms, particularly c. 516G→ T, are strongly associated with plasma efavirenz …
polymorphisms, particularly c. 516G→ T, are strongly associated with plasma efavirenz …
Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers
P Zubiaur, M Saiz-Rodriguez, D Ochoa… - The …, 2020 - nature.com
Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line therapy for the
treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well …
treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well …